The framework for diagnosis and prospective treatments in prostate cancer have already been described, which also demonstrated the increased risk of genomic loss of BMPR1a enriched in metastatic castrate resistant prostate cancer.41 This evidence concerns the gene BMPR1A and prostate carcinoma.